A Solution to the ALS Diagnostic Delay

The amyotrophic lateral sclerosis (ALS) diagnostic journey is unique to each individual. It has puzzled neurologists, been mistaken for allergies or back issues by physicians, stressed out families, and most significantly, it has prevented patients from knowing what is affecting their body.

The median diagnostic delay for a person living with ALS is 12 months (Martharan, 2020). In other words, from the time of their first symptom onset, it takes roughly a year to positively diagnose someone with ALS. Not only that, but each person living with ALS sees an average of three different physicians before receiving their ALS diagnosis (Paganoni, 2014). In the world of rare diseases, this diagnostic delay is not uncommon, but on a patient level, this lag can be life threatening. Not only does the delay prevent patients from seeking the correct medical attention for their symptoms, but it also reduces the time frame a patient has to enroll in clinical trials.

So, if it really takes a year to get diagnosed with ALS, where does all the time go? According to peer reviewed literature, there are three key stages that have quantifiable lags (Paganoni, 2014).

    • Time from symptom onset to the first doctor visit: 4 months
    • Time from the first doctor visit to a suspected ALS diagnosis: 3 months
    • Time from suspected to confirmed ALS diagnosis: 1 month

Research studies have also been conducted to analyze what factors delay or accelerate an ALS diagnosis:

    • Patients age 60 and older: delayed ALS diagnosis
    • The presence of fasciculations, slurred speech, and lower extremity weakness when symptoms are first noted: accelerated ALS diagnosis
    • Sporadic ALS and limb onset: delayed ALS diagnosis

If we analyze the above diagnostic delay predictors in each individual ALS case, we can start to break down what really is at the root of a delayed diagnosis. Was it the patient’s stubbornness and refusal to go to the doctor? Was it a primary care physician failing to identify the patterns of a highly complex disease or not wanting to give a fatal diagnosis? More than likely, it was a culmination of multiple variables. The author of this blog has identified four key categories of dysfunction that influence the ALS diagnostic process: public knowledge, the medical system, the pharmaceutical industry, and ALS disease complexity. There are specific failures within each category. The charts below list these points of failure.

Compensating for each of these system failures will take, and is taking, years and millions of dollars. Is there a simpler solution? Or do we approach each of these system inefficiencies individually? Yes, there is a simpler solution. Machine learning is proving to be the solution. Mitsubishi Tanabe (MT) Pharma, the company known for developing the ALS therapy, endaravone, is hard at work. They have created a program that interfaces with billing codes within our medical systems. The software is trained to identify potential ALS patients before they receive their ALS diagnosis. How is this possible? MT Pharma acquired historical claims data on Truven from 14,000 ALS patients during the 5 years leading up to their ALS diagnosis. They looked for patterns in the billing codes and created an algorithm to detect similar patterns. This early detection software was in the beta testing stages in December 2019 and will hopefully be utilized in the near future. The early stage testing results revealed the software had a 14% positive predictive value. In other words, roughly 1 out of every 9 people who were flagged by the system were correctly identified as having ALS. This early detection method not only has implications in ALS, but in the larger populations of patients at risk of developing neurodegenerative diseases such as Parkinson’s and Alzheimer’s.

This solution to the ALS diagnostic delay highlights two important points: it warns the public that they should never underestimate a pharmaceutical company’s ability to find customers, and it reveals that rare disease populations can benefit from pharmaceutical marketing budgets. Does this solution imply we should stop working on the systematic inefficiencies that allow patients with rare diseases to fall through the cracks? Absolutely not. Leslie Sands is living with ALS in San Luis Obispo. These are her recommendations for medical professionals everywhere:

    • A local specialist or primary care physician (PA’s and NP’s included) should urgently refer their patient to a university or a major hospital neurology center for evaluation when: they encounter a patient with unexplained slurred speech and have ruled out a stroke, traumatic brain injury, or other “obvious” conditions, and the patient’s labs are inconclusive with no obvious alerts.
    • The local doctor should not “suggest” that the patient seeing a neurologist associated with a university or major hospital may be a good idea; rather, the local doctor should emphasize the importance of seeing a qualified neurologist.
    • The local doctor or specialist should not be afraid to broach the possibility of a motor neuron disease (MND).

Leslie’s recommendations are echoed by ALS researchers who have collected data on patients who received a diagnosis far too delayed into their disease experience. One incredible ALS advocate, Sandy Morris, recommends that anyone who thinks they may have ALS symptoms, goes to a local emergency room and doesn’t leave until they receive a diagnosis. Hey, that’s one way to do it.

As with most complex problems, it is a combination of disciplines that need to collaboratively work towards a solution. While ALS patients encourage medical professionals to heighten their awareness of ALS, MT Pharma’s early detection algorithm will assist the doctors with the pattern recognition needed to correctly diagnose neurodegenerative diseases.

Related Articles:

Diagnostic Delays in ALS ‘Surprisingly Large’ and Need Not Be, Study Says

References

Martharan, Martin, Mathis, Stephane, Bonabaud, Sarah. (2020). Minimizing the Diagnostic Delay in Amyotrophic Lateral Sclerosis: The Role of Nonneurologist Practitioners. Neurology Research International. Volume 2020 Article ID 1473981, 8 pages.

Paganoni, S., Macklin, E. A., Lee, A., Murphy, A., Chang, J., Zipf, A., Cudkowicz, M., & Atassi, N. (2014). Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS). Amyotrophic lateral sclerosis & frontotemporal degeneration, 15(5-6), 453–456.

Neil Clayton
Development Coordinator
MOFF is pleased to welcome Neil Clayton to the MOFF team as Development Coordinator and Strategic Thought Partner. Neil joins MOFF after working in law enforcement in San Luis Obispo County for over 20 years. During his law enforcement career, Neil volunteered with law enforcement-related non profits at both the local and state level. Neil recently retired from the SLO County District Attorney’s Office.

Neil supports MOFF’s mission and shares our organizational values having experienced the loss of a loved one to ALS in 2015. Driven by his experience with the challenges of caring for a loved one battling this disease locally, Neil is determined to help families living on the Central Coast find and maintain the medical care they need as well as do everything possible to support finding a cure.

In his spare time, Neil enjoys hiking, fishing and traveling with his wife Jennifer and their two children.

Gabriella Lyon
Social Media Coordinator
Gabriella is the Coordinator for Administrative Support at Associated Students, Inc. at Cal Poly San Luis Obispo. In her spare time, she serves as the Social Media Coordinator for MOFF. With a background in advocacy work and a personal understanding of the impact ALS has on families, Gabriella is committed to supporting and uplifting the ALS community. She holds a Bachelor of Arts degree in Communication and Sociology from the University of California, Davis.

Natalie Fernandez
Program Director, COO/CFO
Natalie is a Senior Consultant at Beghou Consulting. In her spare time she serves as Fractional COO/ CFO at MOFF. She is part of the Community Research Committee at the ALS Network and is a member of the Patient and Caregiver Advisory Committee at the ALS Association. Natalie holds an MBA degree in Pharmaceutical and Healthcare Business from the Philadelphia College of Pharmacy and an undergraduate degree from NYU. Natalie is motivated to find a cure for ALS to prevent individuals from experiencing what her mother, Martha, went through in her ALS journey. Natalie joined the ALS community when the saying was “ALS is not an incurable disease, it was just an underfunded one.” Today, it is now well funded. Let’s go! #findacureforALS

Andrea O'Brien
Board Member, Co-Founder, Secretary
Andrea O'Brien is a former HR professional who brings a wealth of experience in people and business to her role as Board Member, Co-Founder and Secretary at the Martha Olson-Fernandez Foundation. She holds a bachelor's degree from California Polytechnic State University and after building her professional career, she chose to dedicate her time to raising her son and daughter, embracing the opportunity to be present for their early years and family life. Her commitment to the Foundation is deeply personal, inspired by its namesake, her mother, Martha. Through her service, she honor's Martha's strength and resilience while advancing awareness, support and resources for individuals and families affected by ALS. She is proud to combine her professional experience and personal passion in support of the Foundation's mission.

John Ronca
Board Member
John joined the MOFF board of directors in April 2020. Bio coming soon.

Cheri Humphrey
Board Member
Cheri Humphrey joined the MOFF board of directors in August of 2019. Cheri grew up in Dixon, CA and moved to San Luis Obispo to attend Cal Poly. It was there that she met her husband Jim. They now reside in SLO and have a daughter, Victoria and a son, Riley. Cheri is instrumental in the operations of the iconic Madonna Inn, which she has been the Retail Manager of since 1989. Cheri and her family have been ALS advocates since the inception of MOFF. We are honored to have Cheri as part of the board to guide community outreach and continue raising awareness of ALS prevalence on the Central Coast.

Ian Parkinson
Board Member
We are very excited to welcome San Luis Obispo County Sheriff, Ian Parkinson, into his second two-year term as a member of the Martha Olson-Fernandez Foundation Board. Ian has served as Sheriff since 2011 and is well known in the community for this tireless efforts to improve the law enforcement processes of SLO County. Ian knew Martha Olson-Fernandez and has been a supporter of MOFF since 2012. We are very grateful for his commitment to help us carry out our mission to fight ALS through patient care and research. We look forward to utilizing his strategic insights and community outreach to further the MOFF mission.

Larry Fernandez
Director, CEO
Larry is a consultant in the vegetable seed industry. He has been an entrepreneur in the vegetable seed industry for 40 plus years. Larry is very proud of his daughter’s scholastic achievements, working careers and their growing families. He enjoys being a grandpa 3 times over, hunting and fishing when time permits. His goal in life is to honor his wife (Martha Olson-Fernandez) wishes of Finding a cure for ALS and assisting those living with ALS today so they never have to go through the processes she did while living with ALS.